Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Gynecology

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 91 articles:
HTML format



Single Articles


    April 2021
  1. YANG WT, Chen M, Xu R, Zheng PS, et al
    PRDM4 inhibits cell proliferation and tumorigenesis by inactivating the PI3K/AKT signaling pathway through targeting of PTEN in cervical carcinoma.
    Oncogene. 2021 Apr 12. pii: 10.1038/s41388-021-01765.
    PubMed     Abstract available


    March 2021
  2. NI M, Li J, Zhao H, Xu F, et al
    BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
    Oncogene. 2021 Mar 12. pii: 10.1038/s41388-021-01735.
    PubMed     Abstract available


  3. ALI R, Alblihy A, Miligy IM, Alabdullah ML, et al
    Molecular disruption of DNA polymerase beta for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
    Oncogene. 2021 Mar 5. pii: 10.1038/s41388-021-01710.
    PubMed     Abstract available


    February 2021
  4. MORGAN EL, Patterson MR, Barba-Moreno D, Scarth JA, et al
    The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer.
    Oncogene. 2021 Feb 24. pii: 10.1038/s41388-021-01679.
    PubMed     Abstract available


  5. XING Y, Chen L, Gu H, Yang C, et al
    Downregulation of NUDT21 contributes to cervical cancer progression through alternative polyadenylation.
    Oncogene. 2021 Feb 22. pii: 10.1038/s41388-021-01693.
    PubMed     Abstract available


    January 2021
  6. XIAO Y, Jin L, Deng C, Guan Y, et al
    Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01621.
    PubMed     Abstract available


  7. YOSHIDA K, Yokoi A, Sugiyama M, Oda S, et al
    Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01595.
    PubMed     Abstract available


  8. NOH K, Bach DH, Choi HJ, Kim MS, et al
    The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.
    Oncogene. 2021;40:384-395.
    PubMed     Abstract available


    November 2020
  9. SONG Y, Wang M, Tong H, Tan Y, et al
    Plasma exosomes from endometrial cancer patients contain LGALS3BP to promote endometrial cancer progression.
    Oncogene. 2020 Nov 18. pii: 10.1038/s41388-020-01555.
    PubMed     Abstract available


    October 2020
  10. ZHANG Q, Zhou W, Yu S, Ju Y, et al
    Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation.
    Oncogene. 2020 Oct 20. pii: 10.1038/s41388-020-01516.
    PubMed     Abstract available


  11. RANZUGLIA V, Lorenzon I, Pellarin I, Sonego M, et al
    Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
    Oncogene. 2020;39:6370-6386.
    PubMed     Abstract available


  12. REN S, Gaykalova DA, Guo T, Favorov AV, et al
    HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers.
    Oncogene. 2020;39:6327-6339.
    PubMed     Abstract available


    September 2020
  13. XU Z, Li X, Li H, Nie C, et al
    Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01482.
    PubMed     Abstract available


  14. MEHNER C, Miller E, Hockla A, Coban M, et al
    Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
    Oncogene. 2020 Sep 14. pii: 10.1038/s41388-020-01451.
    PubMed     Abstract available


    August 2020
  15. WANG X, Wendel JRH, Emerson RE, Broaddus RR, et al
    Pten and Dicer1 loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma.
    Oncogene. 2020 Aug 25. pii: 10.1038/s41388-020-01434.
    PubMed     Abstract available


    July 2020
  16. ZHOU Y, Liu F, Xu Q, Yang B, et al
    Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer.
    Oncogene. 2020 Jul 13. pii: 10.1038/s41388-020-1384.
    PubMed     Abstract available


  17. NAIR J, Huang TT, Murai J, Haynes B, et al
    Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.
    Oncogene. 2020 Jul 9. pii: 10.1038/s41388-020-1383.
    PubMed     Abstract available


    May 2020
  18. LI J, Alvero AB, Nuti S, Tedja R, et al
    CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential.
    Oncogene. 2020;39:3965-3979.
    PubMed     Abstract available


    April 2020
  19. PELLARIN I, Dall'Acqua A, Gambelli A, Pellizzari I, et al
    Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity.
    Oncogene. 2020 Apr 24. pii: 10.1038/s41388-020-1292.
    PubMed     Abstract available


  20. YANG G, Rosen DG, Colacino JA, Mercado-Uribe I, et al
    Correction: Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells.
    Oncogene. 2020 Apr 17. pii: 10.1038/s41388-020-1294.
    PubMed     Abstract available


  21. KAN T, Wang W, Ip PP, Zhou S, et al
    Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites.
    Oncogene. 2020 Apr 13. pii: 10.1038/s41388-020-1288.
    PubMed     Abstract available


    March 2020
  22. CHOI PW, So WW, Yang J, Liu S, et al
    MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread.
    Oncogene. 2020 Mar 25. pii: 10.1038/s41388-020-1264.
    PubMed     Abstract available


  23. TAMURA R, Yoshihara K, Nakaoka H, Yachida N, et al
    XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.
    Oncogene. 2020 Mar 2. pii: 10.1038/s41388-020-1237.
    PubMed     Abstract available


  24. HAYASHI T, Sano K, Aburatani H, Yaegashi N, et al
    Initialization of epithelial cells by tumor cells in a metastatic microenvironment.
    Oncogene. 2020;39:2638-2640.
    PubMed    


    February 2020
  25. CHEN C, Gupta P, Parashar D, Nair GG, et al
    ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis.
    Oncogene. 2020 Feb 6. pii: 10.1038/s41388-020-1194.
    PubMed     Abstract available


    January 2020
  26. KWEON J, Jang AH, Shin HR, See JE, et al
    A CRISPR-based base-editing screen for the functional assessment of BRCA1 variants.
    Oncogene. 2020;39:30-35.
    PubMed     Abstract available


  27. ZHOU Y, Liu H, Wang J, Wang X, et al
    DeltaNp63alpha exerts antitumor functions in cervical squamous cell carcinoma.
    Oncogene. 2020;39:905-921.
    PubMed     Abstract available


    November 2019
  28. CLUZET V, Devillers MM, Petit F, Chauvin S, et al
    Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary.
    Oncogene. 2019 Nov 19. pii: 10.1038/s41388-019-1109.
    PubMed     Abstract available


  29. KIM YS, Gupta Vallur P, Jones VM, Worley BL, et al
    Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells.
    Oncogene. 2019 Nov 13. pii: 10.1038/s41388-019-1097.
    PubMed     Abstract available


  30. SUN C, Li X, Guo E, Li N, et al
    MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis.
    Oncogene. 2019 Nov 8. pii: 10.1038/s41388-019-1090.
    PubMed     Abstract available


  31. ASARE-WEREHENE M, Nakka K, Reunov A, Chiu CT, et al
    The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.
    Oncogene. 2019 Nov 7. pii: 10.1038/s41388-019-1087.
    PubMed     Abstract available


    September 2019
  32. TUNG CH, Kuo LW, Huang MF, Wu YY, et al
    MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer.
    Oncogene. 2019 Sep 30. pii: 10.1038/s41388-019-1025.
    PubMed     Abstract available


  33. ZHAO L, Wang W, Xu L, Yi T, et al
    Correction: Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.
    Oncogene. 2019 Sep 3. pii: 10.1038/s41388-019-0896.
    PubMed     Abstract available


  34. ZHANG MH, Zhang HH, Du XH, Gao J, et al
    UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-kappaB pathway.
    Oncogene. 2019 Sep 2. pii: 10.1038/s41388-019-0987.
    PubMed     Abstract available


    August 2019
  35. ZENG YT, Liu XF, Yang WT, Zheng PS, et al
    REX1 promotes EMT-induced cell metastasis by activating the JAK2/STAT3-signaling pathway by targeting SOCS1 in cervical cancer.
    Oncogene. 2019 Aug 13. pii: 10.1038/s41388-019-0906.
    PubMed     Abstract available


  36. HAN Y, Kim B, Cho U, Park IS, et al
    Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells.
    Oncogene. 2019 Aug 13. pii: 10.1038/s41388-019-0949.
    PubMed     Abstract available


    July 2019
  37. HAN X, Ren C, Yang T, Qiao P, et al
    Negative regulation of AMPKalpha1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer.
    Oncogene. 2019 Jul 29. pii: 10.1038/s41388-019-0898.
    PubMed     Abstract available


  38. KLEINSCHMIDT EG, Miller NLG, Ozmadenci D, Tancioni I, et al
    Rgnef promotes ovarian tumor progression and confers protection from oxidative stress.
    Oncogene. 2019 Jul 15. pii: 10.1038/s41388-019-0881.
    PubMed     Abstract available


  39. HARDY LR, Pergande MR, Esparza K, Heath KN, et al
    Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.
    Oncogene. 2019 Jul 11. pii: 10.1038/s41388-019-0842.
    PubMed     Abstract available


  40. CHEN X, Mangala LS, Mooberry L, Bayraktar E, et al
    Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.
    Oncogene. 2019 Jul 9. pii: 10.1038/s41388-019-0862.
    PubMed     Abstract available


  41. MAJEM B, Parrilla A, Jimenez C, Suarez-Cabrera L, et al
    MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.
    Oncogene. 2019 Jul 5. pii: 10.1038/s41388-019-0860.
    PubMed     Abstract available


    May 2019
  42. CAO T, Jiang Y, Wang Z, Zhang N, et al
    H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas.
    Oncogene. 2019 May 15. pii: 10.1038/s41388-019-0808.
    PubMed     Abstract available


    April 2019
  43. HONG S, Xu J, Li Y, Andrade J, et al
    Topoisomerase IIbeta-binding protein 1 activates expression of E2F1 and p73 in HPV-positive cells for genome amplification upon epithelial differentiation.
    Oncogene. 2019;38:3274-3287.
    PubMed     Abstract available


    March 2019
  44. JEONG KJ, Park SY, Cho KH, Sohn JS, et al
    Correction: The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
    Oncogene. 2019 Mar 29. pii: 10.1038/s41388-019-0769.
    PubMed     Abstract available


    February 2019
  45. JOHN B, Naczki C, Patel C, Ghoneum A, et al
    Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC.
    Oncogene. 2019 Feb 14. pii: 10.1038/s41388-019-0728.
    PubMed     Abstract available


  46. INESS AN, Felthousen J, Ananthapadmanabhan V, Sesay F, et al
    The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.
    Oncogene. 2019;38:1080-1092.
    PubMed     Abstract available


  47. ZHOU CF, Ma J, Huang L, Yi HY, et al
    Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1.
    Oncogene. 2019;38:1256-1268.
    PubMed     Abstract available


    January 2019
  48. DONG P, Xiong Y, Yu J, Chen L, et al
    Correction: Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
    Oncogene. 2019 Jan 24. pii: 10.1038/s41388-019-0677.
    PubMed     Abstract available


  49. HUANG CC, Cheng SH, Wu CH, Li WY, et al
    Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.
    Oncogene. 2019 Jan 9. pii: 10.1038/s41388-018-0658.
    PubMed     Abstract available


  50. JING Y, Zhang Y, Zhu H, Zhang K, et al
    Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer.
    Oncogene. 2019 Jan 7. pii: 10.1038/s41388-018-0644.
    PubMed     Abstract available


    December 2018
  51. MOTOHARA T, Masuda K, Morotti M, Zheng Y, et al
    An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.
    Oncogene. 2018 Dec 19. pii: 10.1038/s41388-018-0637.
    PubMed     Abstract available


  52. LIU S, Yin P, Kujawa SA, Coon JS 5th, et al
    Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma.
    Oncogene. 2018 Dec 11. pii: 10.1038/s41388-018-0612.
    PubMed     Abstract available


  53. GRABOSCH S, Bulatovic M, Zeng F, Ma T, et al
    Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
    Oncogene. 2018 Dec 5. pii: 10.1038/s41388-018-0581.
    PubMed     Abstract available


    November 2018
  54. ZHAO L, Wang W, Xu L, Yi T, et al
    Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.
    Oncogene. 2018 Nov 26. pii: 10.1038/s41388-018-0577.
    PubMed     Abstract available


  55. WUSTENHAGEN E, Boukhallouk F, Negwer I, Rajalingam K, et al
    The Myb-related protein MYPOP is a novel intrinsic host restriction factor of oncogenic human papillomaviruses.
    Oncogene. 2018;37:6275-6284.
    PubMed     Abstract available


    October 2018
  56. MCLEAN K, Tan L, Bolland DE, Coffman LG, et al
    Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
    Oncogene. 2018 Oct 10. pii: 10.1038/s41388-018-0523.
    PubMed     Abstract available


    September 2018
  57. ZHONG Y, Yang S, Wang W, Wei P, et al
    The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer.
    Oncogene. 2018 Sep 28. pii: 10.1038/s41388-018-0512.
    PubMed     Abstract available


    August 2018
  58. SUN J, Cai X, Yung MM, Zhou W, et al
    miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
    Oncogene. 2018 Aug 30. pii: 10.1038/s41388-018-0459.
    PubMed     Abstract available


    July 2018
  59. HODGKINSON K, Forrest LA, Vuong N, Garson K, et al
    GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer.
    Oncogene. 2018 Jul 4. pii: 10.1038/s41388-018-0377.
    PubMed     Abstract available


  60. ZHOU W, Sun W, Yung MMH, Dai S, et al
    Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.
    Oncogene. 2018;37:3981-3997.
    PubMed     Abstract available


    June 2018
  61. BAI M, Yang L, Liao H, Liang X, et al
    Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.
    Oncogene. 2018 Jun 19. pii: 10.1038/s41388-018-0360.
    PubMed     Abstract available


  62. OZES AR, Pulliam N, Ertosun MG, Yilmaz O, et al
    Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
    Oncogene. 2018;37:3589-3600.
    PubMed     Abstract available


    May 2018
  63. DONG P, Xiong Y, Yu J, Chen L, et al
    Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
    Oncogene. 2018 May 31. pii: 10.1038/s41388-018-0347.
    PubMed     Abstract available


  64. SO D, Shin HW, Kim J, Lee M, et al
    Cervical cancer is addicted to SIRT1 disarming the AIM2 antiviral defense.
    Oncogene. 2018 May 29. pii: 10.1038/s41388-018-0339.
    PubMed     Abstract available


  65. AL HABYAN S, Kalos C, Szymborski J, McCaffrey L, et al
    Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer.
    Oncogene. 2018 May 23. pii: 10.1038/s41388-018-0317.
    PubMed     Abstract available


  66. GABBASOV R, Xiao F, Howe CG, Bickel LE, et al
    NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice.
    Oncogene. 2018 May 18. pii: 10.1038/s41388-018-0296.
    PubMed     Abstract available


  67. RADA M, Nallanthighal S, Cha J, Ryan K, et al
    Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
    Oncogene. 2018 May 17. pii: 10.1038/s41388-018-0297.
    PubMed     Abstract available


  68. BERNS K, Caumanns JJ, Hijmans EM, Gennissen AMC, et al
    ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
    Oncogene. 2018 May 15. pii: 10.1038/s41388-018-0300.
    PubMed     Abstract available


    April 2018
  69. WANG S, Li J, Xie J, Liu F, et al
    Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin beta4/SNAI1/SIRT3 signaling pathway.
    Oncogene. 2018 Apr 30. pii: 10.1038/s41388-018-0252.
    PubMed     Abstract available


  70. YU Y, Suryo Rahmanto Y, Lee MH, Wu PH, et al
    Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway.
    Oncogene. 2018 Apr 11. pii: 10.1038/s41388-018-0241.
    PubMed     Abstract available


  71. DORAYAPPAN KDP, Wanner R, Wallbillich JJ, Saini U, et al
    Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins.
    Oncogene. 2018 Apr 11. pii: 10.1038/s41388-018-0189.
    PubMed     Abstract available


    March 2018
  72. PETA E, Sinigaglia A, Masi G, Di Camillo B, et al
    HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
    Oncogene. 2018;37:1654-1668.
    PubMed     Abstract available


    February 2018
  73. LIU F, Dai M, Xu Q, Zhu X, et al
    SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-kappaB-CD47 axis.
    Oncogene. 2018 Feb 12. pii: 10.1038/s41388-017-0119.
    PubMed     Abstract available


  74. MITAMURA T, Pradeep S, McGuire M, Wu SY, et al
    Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).
    Oncogene. 2018;37:722-731.
    PubMed     Abstract available


  75. LIU Y, Zhou H, Zhu R, Ding F, et al
    SPSB3 targets SNAIL for degradation in GSK-3beta phosphorylation-dependent manner and regulates metastasis.
    Oncogene. 2018;37:768-776.
    PubMed     Abstract available


  76. LADANYI A, Mukherjee A, Kenny HA, Johnson A, et al
    Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
    Oncogene. 2018 Feb 5. pii: 10.1038/s41388-017-0093.
    PubMed     Abstract available


    January 2018
  77. AKHTER MZ, Sharawat SK, Kumar V, Kochat V, et al
    Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0106.
    PubMed     Abstract available


  78. GHANNAM-SHAHBARI D, Jacob E, Kakun RR, Wasserman T, et al
    PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0040.
    PubMed     Abstract available


  79. RUSSO A, Czarnecki AA, Dean M, Modi DA, et al
    PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0097.
    PubMed     Abstract available


  80. GRITHER WR, Divine LM, Meller EH, Wilke DJ, et al
    TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.
    Oncogene. 2018 Jan 19. pii: 10.1038/s41388-017-0043.
    PubMed     Abstract available


  81. NAGARAJ AB, Wang QQ, Joseph P, Zheng C, et al
    Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.
    Oncogene. 2018;37:403-414.
    PubMed     Abstract available


  82. CORKERY DP, Clarke LE, Gebremeskel S, Salsman J, et al
    Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking.
    Oncogene. 2018;37:174-184.
    PubMed     Abstract available


    November 2017
  83. ZHONG Y, Yang J, Xu WW, Wang Y, et al
    KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition.
    Oncogene. 2017;36:6177-6189.
    PubMed     Abstract available


    October 2017
  84. WANG J, Kho DH, Zhou JY, Davis RJ, et al
    MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.
    Oncogene. 2017;36:5939-5947.
    PubMed     Abstract available


    September 2017
  85. BIAN X, Gao J, Luo F, Rui C, et al
    PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Oncogene. 2017 Sep 25. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  86. YOO JY, Yang WS, Lee JH, Kim BG, et al
    MIG-6 negatively regulates STAT3 phosphorylation in uterine epithelial cells.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  87. RAMADOSS S, Sen S, Ramachandran I, Roy S, et al
    Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  88. YAMAGUCHI H, Du Y, Nakai K, Ding M, et al
    EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  89. GUO H, Zhu Q, Yu X, Merugu SB, et al
    Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.
    Oncogene. 2017;36:5098-5109.
    PubMed     Abstract available


    July 2017
  90. ZHANG Y, Ren YJ, Guo LC, Ji C, et al
    Nucleus accumbens-associated protein-1 promotes glycolysis and survival of hypoxic tumor cells via the HDAC4-HIF-1alpha axis.
    Oncogene. 2017;36:4171-4181.
    PubMed     Abstract available


    April 2017
  91. NIU N, Mercado-Uribe I, Liu J
    Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells.
    Oncogene. 2017 Apr 24. doi: 10.1038/onc.2017.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: